Heron Therapeutics, Inc.

Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Heron Therapeutics First Quarter 2022 Earnings Conference. As a reminder, this conference is being recorded. Now I would like to turn the call over to David Sekaris, Executive Vice President, Chief Operating Officer. Please proceed.

Thank you, Jason. Good afternoon, everyone, and thank you for joining us. With me today from Heron are Barry Cort, Chief Executive Officer and Chairman of John Poynan, President and Chief Commercial Officer, and Kimberly Manhard, Executive Vice President of Drug Development and Board Director. For those of you participating via conference call, the slides are made available via webcast. It can also be accessed by going to the Investor Relations page of our website following conclusion of today's call. Before we begin, I would like to remind you that this call will contain forward-looking statements concerning Heron's future expectations plans, prospects, corporate strategy, and performance, which constitute forward-looking statements for the purposes of the safe harbor provision under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our findings with the SEC. In addition, Any forward-looking statements represent our views only as of the date of this webcast and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligations to update such statements. Now, I'll turn the call over to Barry.

Thank you, David. Welcome, everyone, and thank you for joining us. First quarter was a major turning point for the commercialization of Zen Relief. with the official rollout of expanded indications obtained mid-December. You will hear from John that we are now reaching critical mass in terms of ordering accounts with a 68 percent increase in unit demand in first quarter compared to fourth quarter. This has allowed us to make significant progress in reducing the excess inventory at distribution centers. So next quarter, you should see dollar sales of 400 milligram vials match demand. With continued increases in ordering accounts, formulary approvals, and pass-through status, and multiple IDNs moving towards therapeutic interchange with Zen Relief, we anticipate seeing similar to greater quarter-over-quarter increases in coming quarters. With our CINV franchise, as we noted last quarter, we observed modest growth and are feeling sufficiently confident in this market post-COVID related disruptions to provide guidance for full year 2022. During first quarter, we continued to prosecute our NDA for HDX 019 for post-operative nausea PONV. which has the potential to be many times larger than our CINV business. There are no outstanding information requests from FDA, and they have already provided initial labeling comments. Lastly, we've continued to focus our energies on both cutting costs and partnering ex-US territories for ZIN relief to extend our cash runway. We've made significant progress in both areas with our goal of completing at least one partnership this quarter. Overall, first quarter was an important turning point for Heron, and we're excited to review our progress with you today. I will now turn the call over to John to review our achievement of important commercial and corporate milestones. John?